Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tragrisso

- PMLiVE

Lilly buoyant as lung cancer hope clears pivotal study

Necitumumab on course for regulatory submission in 2014

- PMLiVE

GSK submits Votrient for ovarian cancer in Europe

Pharma company hopes for extra indication for oncology product

EU flag

EC sets up expert group on rare diseases

Will revamp EUCERD to better handle development of orphan medicines

- PMLiVE

EMA’s head of human medicines development steps down

Patrick Le Courtois leaves regulator after 16 years

- PMLiVE

AZ inks $815m deal for FibroGen anaemia drug

Deal comes as company reveals second quarter performance

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

- PMLiVE

Pfizer and Otsuka face drug rejections in Europe

EMA turns down Xeljanz for rheumatoid arthritis and delamanid for tuberculosis

- PMLiVE

EMA: no new safety concerns with GLP-1 diabetes drugs

CHMP takes issue with study that linked the treatments to serious side effects

- PMLiVE

AZ and BMS try again with Forxiga in the US

Pharma companies re-submit diabetes drug to the FDA for approval

Biogen Idec building

Biogen Idec’s long-acting beta interferon moves ahead in MS

US and EU accept filings for long-acting multiple sclerosis drug Plegridy

China flag thumb

AstraZeneca and UCB drawn into Chinese investigations

Follows country’s clampdown on GSK bribery

- PMLiVE

Leaked EFPIA memo reveals transparency strategy

Includes plans to use patient groups to support campaign against greater access to trial data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links